SARS-CoV2 Infection and Comorbidities, Role in Oncogenesis

Spirina, Liudmila V; Masunova, Nadezhda V; Masunov, Vladimir N; Makova, Victoria V; Dagbaeva, Yumzhana S; Kovaleva, Irina V

doi:10.31557/APJCP.2022.23.7.2191

SARS-CoV2 Infection and Comorbidities, Role in Oncogenesis

Document Type : Systematic Review and Meta-analysis

Authors

¹ Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 5 Koopertivny street, Tomsk, 634050, Russia.

² Siberian State Medical University, 2, Moskovsky trakt, Tomsk, 634050, Russia.

³ Second Medical Unit, Department of Health, Tomsk Region, 3, Bela Kun Street, Tomsk, 634050, Russia.

10.31557/APJCP.2022.23.7.2191

Abstract

The widespread infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) significantly impacts major human diseases. It is undoubtedly evident that cancer patients are more susceptible to the infection and at a higher risk of severe COVID-19 than the general population. Moreover, the rise in cancers incidence is waiting in the Globe as a long-term effect of post-COVID-19 complications. Multiple mostly unknown mechanisms participate and determine the oncogenic impact of virus-induced transformation. Imbalance in oncogenesis is considered critical in cancer development. Modified immunogenicity and metabolic features emerge as pivotal in COVID-19 pathogenesis and the organism system’s response. The molecular mechanisms of the onset of the metabolic disorder have not yet been fully elucidated. The pathology is complicated, multifactorial, and emerging in various processes. Preventive anticancer therapy taking into account the change in metabolic processes, helps them respond better to anti-COVID-19 treatment than relying only on antiviral drugs. The modified therapeutic algorithm was provided to reduce the likelihood of post-acute complications in patients with preexisting pathologies and the onset of other chronic pathologies and cancers.

Keywords

Main Subjects